Viral Pleuritis - Biotech, Pharma and Life Science Channel

08:27 EDT 2nd October 2014 | BioPortfolio

Viral pleuritis is a viral infection of the pleurae.

Viral pleuritis is most commonly caused by infection with coxsackie B virus. Occasionally, echovirus causes a rare condition known as epidemic or Bornholm's pleurodynia, manifesting as pleuritis, fever, and chest muscle spasms. The condition occurs in the late summer and affects adolescents and young adults. The primary symptom of viral pleuritis is pleuritic pain; pleural friction rub may be a sign.  Diagnosis is suspected in patients with pleuritic chest pain with or without systemic symptoms of viral infection. Chest x-ray is usually done. Other causes of pleuritic chest pain, such as pulmonary emboli and pneumonia, need to be considered and sometimes ruled out with testing. Treatment is symptomatic, with oral NSAIDs or a short course of oral opioids if needed.

Soruce; Merck Manuals

Add the Pleuritis News Channel to your RSS reader;

PubMed Articles [2530 Associated PubMed Articles listed on BioPortfolio]

Reverse genetic engineering of the human rhinovirus serotype 16 genome to introduce an antibody-detectable tag.

The ability to accurately detect viral proteins during infection is essential for virology research, and the lack of specific antibodies can make this detection difficult. Reverse genetic engineering ...

Reverse genetics system for studying human rhinovirus infections.

Human rhinovirus (HRV) contains a 7.2 kb messenger-sense RNA genome which is the template for reproducing progeny viruses after it enters the cytoplasm of a host cell. Reverse genetics refers to the r...

Proteases of human rhinovirus: role in infection.

Human rhinoviruses (HRV) are the major etiological agents of the common cold and asthma exacerbations, with significant worldwide health and economic impact. Although large-scale population vaccinatio...

Infectivity assays of human rhinovirus-a and -B serotypes.

Infectivity is a fundamental property of viral pathogens such as human rhinoviruses (HRVs). This chapter describes two methods for measuring the infectivity of HRV-A and -B serotypes: end point diluti...

Molecular genotyping of human rhinovirus by using PCR and sanger sequencing.

Human rhinovirus (HRV) is the virus most often associated with acute upper respiratory tract infections. Advances in molecular detection have shown that HRV is also the major viral cause of asthma exa...

Molecular identification and quantification of human rhinoviruses in respiratory samples.

PCR-based molecular assays have become standard diagnostic procedures for the identification and quantification of human rhinoviruses (HRVs) and other respiratory pathogens in most, if not all, clinic...

Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow.

Chronic hepatitis B virus (HBV) infection may progress to cirrhosis, hepatocellular carcinoma (HCC) and end-stage liver failure with time. Interruption of this process can only be achieved through eff...

Reply to the letter by He et al. 'Meta-analysis of observational studies: hepatitis C and survival after renal transplant'

Comment on Fabrizi et al.: Meta-analysis of observational studies: hepatitis C and survival after renal transplant.

Gastroenterologists can enhance hepatitis C screening by testing individuals referred for colorectal cancer screening.

News Articles [733 Associated News Articles listed on BioPortfolio]

Ceres Nanosciences, Inc. - Product Pipeline Analysis, 2014 Update

Recently added to the BioPortfolio report store, Ceres Nanosciences, Inc. - Product Pipeline Analysis, 2014 Update is a new report from GlobalData published on 2014-09-17. This 37-page report is avai...

Biocartis SA - Product Pipeline Analysis, 2014 Update

Recently added to the BioPortfolio report store, Biocartis SA - Product Pipeline Analysis, 2014 Update is a new report from GlobalData published on 2014-09-17. This 35-page report is available in PDF...

Global Virus Network Joins Forces with Private Sector to Combat Viral Epidemics

New GVN Business Leadership Council links companies with top virologists to strengthen pandemic preparedness and response The Global Virus Network (GVN), the world’s leading...

NanoViricides Reports FluCide™ Samples Were Shipped To BASi For Start of Safety/Toxicology Studies; Also Reports That Ebola Drug Candidates are Being Synthesized

NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) reports that it has shipped FluCide™ to BASi for the start of toxicology studies. NanoViricides has chosen BioAnalytical ...

Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, t...

Zama Massage Therapeutic Spa Brings Salt Cave Therapy to Portland

PORTLAND, Ore., Oct. 1, 2014 /PRNewswire/ -- Zama Massage is thrilled to announce the opening of Portland's only Salt Cave Therapy Rooms. Beginning October 15, 2014, Zama will add these innovativ...

Johnson & Johnson has acquired Alios BioPharma

Johnson & Johnson announced that it has officially acquired Alios BioPharma for $1.7 billion in cash. The acquisition will come with Alios’ portfolio of potential therapeutics for viral infectio...

J&J acquires viral-disease-drug developer for $1.75B

Alios BioPharma, a South San Francisco, Calif.-based biotech firm focused on developing viral-disease drugs, will be purcha -More- Training Impacts Performance Hands-on training in a bench...

J&J bets $1.75 billion on virology

Johnson & Johnson has signed a deal to acquire Alios BioPharma, a privately-held company focussed on developing therapies for viral diseases, for around $1.75 billion in cash. The acquisition will...

Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial

Events [0 Results]

None

Companies [57 Associated Companies listed on BioPortfolio]

Global Virus Network (GVN)

The Global Virus Network (GVN) is an independent, not for profit organization, comprised of leading medical virologists from Argentina, Australia, Belgium, Canada, China, France, ...

Advanced Biological Laboratories

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc...

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has ...

Meridian Bioscience Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and re...

PaxVax Inc.

PaxVax is a privately held specialty vaccine company founded in 2007. PaxVax is focused on traveler vaccines with an emerging pipeline in biodefense coupled with a social mission ...

Adenovir Pharma AB

Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes. Adenovir Pharma was founded by researchers at the department of Virolo...

SillaJen, Inc.

SillaJen, Inc., headquartered in Busan, South Korea with offices in San Francisco, California is a contract R&D company specializing in the translational and clinical development ...

PaxVax Inc

PaxVax is a privately held company established in 2007 to develop and commercialize innovative vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio,...

Viroclinics Biosciences B.V.

Viroclinics Biosciences BV (Viroclinics) is a virology contract research organization, serving the biopharmaceutical community as a pre-clinical and clinical reference laboratory for supporting the ...

Vivaldi Biosciences Inc.

Vivaldi Biosciences is developing live attenuated influenza vaccines (LAIVs) with the potential for increased effectiveness in the prevention of emerging pandemic influenza and se...

Clinical Trials [620 Associated Clinical Trials listed on BioPortfolio]

A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) to participants with chronic hepatitis C virus (HCV) ...

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

This 6-arm study will assess the efficacy and safety of RO5024048 (R7128) in co mbination with the approved doses of Pegasys (180micrograms sc weekly) + Copegus (1000/1200mg po daily) (SO...

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

This is a Phase 1 randomized, single center, dose-escalation study designed to evaluate the safety and immunogenicity of live, replication competent recombinant Adenovirus type 4-H5N1Influ...

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

This is a single-dose, single-arm, open-label, multicenter pharmacokinetic study of Elvitegravir (EVG). The primary aim is to describe the CSF concentrations of elvitegravir. Participants ...

Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes

The overall hypotheses of this proposal are that discrete phenotypes of HIV Chronic Obstructive Pulmonary disease (COPD) differ in their trajectories, biomarkers, and risk factors and that...

IMPROVE Study(The Individualized Management With PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.

This study will compare the efficacy and safety of 48 weeks and 72 weeks treatme nt with PEGASYS plus ribavirin in patients with non-genotype 2/3 chronic hepatit is C who, after 12 weeks o...

A Study of Selumetinib in Patients With Kaposi's Sarcoma

Cancer is a leading cause of death in individuals living with human immunodeficiency virus (HIV), and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer. KS is caused when i...

Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

Up to 120 patients with chronic hepatitis C will be enrolled in a study of viral kinetics and liver gene expression before and during combination therapy with peginterferon and ribavirin. ...

Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

We propose to test our primary hypothesis that treatment with Peg-IFN-α-2b will result in a decrease in integrated HIV DNA in peripheral blood and tissue in chronically HIV-infected immun...

Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Participants With Hepatitis C Infection (MK-8408-003)

This is a 3-part study of MK-8408 for participants with hepatitis C infection. Successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tole...

Videos

Pleurisy

Pleurisy (also known as pleuritis) is an inflammation of the pleura, the lining surrounding the lungs. There are many possible causes of pleurisy but viral i...

Medical and Biotech [MESH] Definitions

Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.

Immunoglobulins produced as a response to VIRAL ANTIGENS; includes all classes of immunoglobulins elicited by all viral components.

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

A species of gram-negative, facultatively anaerobic coccobacillus-shaped bacteria that has been isolated from pneumonic lesions and blood. It produces pneumonia with accompanying fibrinous pleuritis in swine.

The assembly of VIRAL STRUCTURAL PROTEINS and nucleic acid (VIRAL DNA or VIRAL RNA) to form a VIRUS PARTICLE.

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Infectious-diseases
Latest News Clinical Trials Research Drugs Reports Corporate
Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi; the diseases can be spread, directly or indirectly, from one person to another. Zoonotic diseases are infectious diseases of animals that can caus...

Rheumatology
Latest News Clinical Trials Research Drugs Reports Corporate
Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Dictionary). It is an active area of medical research, because of the d...

Anesthesiology
Latest News Clinical Trials Research Drugs Reports Corporate
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...

Advertisement
review and buy Viral Pleuritis market research data and corporate reports here

Channels Quicklinks